

IMPACT FACTOR 2.7

Indexed in: PubMed



an Open Access Journal by MDPI

Biomarkers in the "Omics" Era

Guest Editors:

Dr. Alfonso Urbanucci

Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway

Dr. Simona Tavolari

Division of Medical Oncology, S. Orsola-Malpighi University Hospital, Bologna, Italy

Deadline for manuscript submissions:

closed (31 July 2022)

Message from the Guest Editors

The rapid development of high-throughput technologies has opened up a new "omics" era providing an unprecedented opportunity for scientists and clinicians to gain deeper insights into cancer molecular mechanisms, even at single cell resolution. The analysis and integration of the data arising from these methodological approaches is revolutionizing daily clinical practice, moving the cancer precision medicine paradigm forward. In this scenario, the identification of tissue and circulating molecular biomarkers with high sensitivity and specificity to be employed for diagnosis, prognosis, and treatment prediction will undoubtedly benefit cancer patients, but only few have been successfully implemented into the clinic.

This Special Issue of *BioTech* includes research articles, short reports, and reviews focused on the employment of "omics" (e.g., genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, microbiomics) technologies for cancer biomarker development both at translational and clinical level.



